ストックスクリーナーアプリを入手
213.12
1.20%
-2.58
プレマーケット:
213.20
0.08
+0.04%
前日終値:
$215.70
開ける：
$215.92
24時間の取引高:
4.67M
Relative Volume:
0.71
時価総額：
$376.54B
収益：
$62.82B
当期純損益:
$3.60B
株価収益率:
105.12
EPS:
2.0274
ネットキャッシュフロー:
$19.98B
1週間 パフォーマンス:
-0.30%
1か月 パフォーマンス:
+7.25%
6か月 パフォーマンス:
-6.39%
1年 パフォーマンス:
+16.29%
1日の値動き範囲:
$211.91
$217.05
1週間の範囲:
$209.50
$220.01
52週間の値動き範囲:
$181.73
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Compare ABBV vs LLY, JNJ, MRK, AZN
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
213.12 | 381.10B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,064.74 | 949.70B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
230.18 | 564.11B | 96.36B | 21.04B | 17.80B | 8.6488 |
MRK
Merck Co Inc
|
119.72 | 302.33B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
187.19 | 290.06B | 60.48B | 10.40B | 8.05B | 3.3297 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-21 | 開始されました | Canaccord Genuity | Buy |
| 2026-02-25 | 開始されました | RBC Capital Mkts | Outperform |
| 2026-02-20 | 開始されました | Barclays | Overweight |
| 2026-01-08 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | 再開されました | UBS | Neutral |
| 2025-12-10 | アップグレード | HSBC Securities | Hold → Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-11-04 | ダウングレード | DZ Bank | Buy → Hold |
| 2025-10-14 | ダウングレード | Erste Group | Buy → Hold |
| 2025-10-01 | ダウングレード | HSBC Securities | Buy → Hold |
| 2025-09-17 | アップグレード | Berenberg | Hold → Buy |
| 2025-08-12 | 再開されました | Piper Sandler | Overweight |
| 2025-08-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-12-05 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-04 | アップグレード | Argus | Hold → Buy |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-06-05 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-05-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-01-29 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-12-11 | アップグレード | Goldman | Neutral → Buy |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-10-30 | アップグレード | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-09-29 | 開始されました | Raymond James | Outperform |
| 2023-07-25 | 開始されました | William Blair | Mkt Perform |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-04-05 | ダウングレード | Argus | Buy → Hold |
| 2023-03-01 | 開始されました | Guggenheim | Buy |
| 2023-02-22 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | アップグレード | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-11-08 | ダウングレード | Societe Generale | Buy → Hold |
| 2022-08-01 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Underperform |
| 2022-05-06 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2022-02-28 | ダウングレード | UBS | Buy → Neutral |
| 2022-02-03 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-03 | 繰り返されました | Barclays | Equal Weight |
| 2022-02-03 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-03 | 繰り返されました | Goldman | Neutral |
| 2022-01-13 | 開始されました | Redburn | Buy |
| 2022-01-12 | 繰り返されました | BMO Capital Markets | Outperform |
| 2021-12-09 | 再開されました | Wells Fargo | Overweight |
| 2021-11-23 | アップグレード | Societe Generale | Hold → Buy |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2020-11-10 | 再開されました | Bernstein | Outperform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-06-23 | アップグレード | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | アップグレード | Argus | Hold → Buy |
| 2020-05-18 | 再開されました | BofA/Merrill | Neutral |
| 2020-05-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 再開されました | Morgan Stanley | Overweight |
| 2020-04-20 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | ダウングレード | Societe Generale | Buy → Hold |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 繰り返されました | Cowen | Outperform |
| 2019-09-26 | アップグレード | Citigroup | Neutral → Buy |
| 2019-08-20 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 開始されました | Goldman | Neutral |
| 2019-04-29 | アップグレード | BMO Capital Markets | Underperform → Market Perform |
すべてを表示
Abbvie Inc (ABBV) 最新ニュース
Price to earnings ratio of AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1 – BCBA:ABBV.CI - TradingView
AbbVie Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
AbbVie (NYSE: ABBV) Form 144: Director proxy to sell $2.78M in shares - Stock Titan
AbbVie Picks North Carolina for Campus - Advanced Manufacturing
Final Trades: AbbVie, Deckers and Goldman Sachs - CNBC
GE Vernova, Estée Lauder, AbbVie: CNBC's 'Final Trades'AbbVie (NYSE:ABBV), Archer-Daniels-Midland (NYS - Benzinga
AbbVie Inc. stock (US00287Y1091): pharma heavyweight between immunology strength and patent reset - AD HOC NEWS
Prediction: These 2 Obesity Drug Stocks Could Double in 2026 - The Motley Fool
AbbVie Inc. (ABBV) Stock Analysis: Unraveling a 17% Potential Upside Amid Robust Buy Ratings - DirectorsTalk Interviews
What's the Better Dividend Stock Today: AbbVie or Pfizer? - Yahoo Finance
AbbVie Expands European Reach As Investors Weigh Dividend Support - Yahoo Finance
Hikari Power Ltd's AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie (ABBV): 10 Best Low Risk Stocks to Buy in 2026 - Yahoo Finance
First Dallas Securities Inc.'s AbbVie Inc(ABBV) Holding History - GuruFocus
Final trades: AbbVie, Millrose Properties, Archer-Daniels-Midland, GE Vernova and Estee Lauder - MSN
KILNER CAPITAL ADVISORS, LLC's AbbVie Inc(ABBV) Holding History - GuruFocus
Final Trades: AbbVie, Millrose Properties, Archer-Daniels-Midland, GE Vernova and Estee Lauder - CNBC
Merck (MRK) and AbbVie (ABBV) Gain EU Panel Endorsements for New Treatments - GuruFocus
AbbVie, Merck, Astra among winners of EU drug recommendations this week - Seeking Alpha
AbbVie (ABBV) Receives Positive EMA Opinion for Maviret Approval - GuruFocus
AbbVie Announces Positive CHMP Opinion for MAVIRET® for the Treatment of Acute Hepatitis C Infection - Investing News Network
AbbVie, Novartis slash US headcount - PharmaLive
AbbVie receives EU panel backing for Maviret in acute hepatitis C - Investing.com Canada
AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection - Yahoo Finance
Opinion: AbbVie Is the Best Dividend King to Buy in an Increasingly Uncertain Market - The Motley Fool
AbbVie to present oncology pipeline data at 2026 ASCO meeting - StreetInsider
Layoff Tracker: AbbVie, Novartis slash US headcount - BioSpace
AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline - Investing News Network
AbbVie stock (US00287Y1091): focus on Humira successors after latest quarterly update - AD HOC NEWS
Allergan Aesthetics Receives Positive CHMP Opinion for Boey® for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults - Investing News Network
AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across Its Next-Generation Oncology Pipeline - Moomoo
AbbVie (ABBV) Receives Positive EMA Opinion for Boey Approval - GuruFocus
AbbVie Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
EU advisers back Allergan’s Boey, a wrinkle shot that works in 8 hours - Stock Titan
Opinion: This program was meant to increase healthcare affordability. The data tell another story. - Crain's Chicago Business
Precision Trading with Abbvie Inc. (ABBV) Risk Zones - Stock Traders Daily
AbbVie Inc. (ABBV) Positioned for Long-Term Gains with IBD Pipeline Strength - Yahoo Finance
AbbVie Inc stock (US00287Y1091): new data, dividend strength and oncology focus draw investor attent - AD HOC NEWS
AbbVie stock (US00287Y1091): focus on immunology pipeline after latest data update - AD HOC NEWS
Three Dividend-Paying Healthcare Giants: Pfizer (PFE), AbbVie (ABBV), and Medtronic (MDT) Compared for 2026 - Blockonomi
High Yield Healthcare Stocks: Why Pfizer, AbbVie, and Medtronic Are Worth Watching in 2026 - CoinCentral
AbbVie stock (US00287Y1091): investors eye Skyrizi and Rinvoq momentum after latest quarterly update - AD HOC NEWS
Here is what to know beyond why AbbVie Inc. (ABBV) is a trending stock - MSN
AbbVie stock (US00287Y1091): Q1 2026 earnings beat and Skyrizi, Rinvoq drive fresh momentum - AD HOC NEWS
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
UCB (UCBJY) Reports Bimzelx Success Over AbbVie's Skyrizi in Pso - GuruFocus
Top 12 Undervalued Dividend Stocks to Buy Now - Insider Monkey
UCB says Bimzelx beat AbbVie’s Skyrizi in psoriatic arthritis trial - Seeking Alpha
AbbVie (ABBV) Price Target Lowered to $235 at Evercore ISI - Insider Monkey
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock - Yahoo Finance
2 Reasons to Like ABBV and 1 to Stay Skeptical - Yahoo Finance
Abbvie Inc (ABBV) 財務データ
収益
当期純利益
現金流量
EPS
2.20%
0.09%
大文字化:
|
ボリューム (24 時間):